• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Study - Regression from prediabetes to normal glucose regulation

Sally Furniss

Well-known member
The Lancet

Effect of regression from prediabetes to normal glucose regulation on long-term reduction in diabetes risk: results from the Diabetes Prevention Program Outcomes Study


Leigh Perreault MD a, Qing Pan b, Kieren J Mather MD c, Karol E Watson MD d, Richard F Hamman MD DrPh e, Steven E Kahn MB ChB f, for the Diabetes Prevention Program Research GroupCorresponding Author

Summary

Background

Our objective was to quantify and predict diabetes risk reduction during the Diabetes Prevention Program Outcomes Study (DPPOS) in participants who returned to normal glucose regulation at least once during the Diabetes Prevention Program (DPP) compared with those who consistently met criteria for prediabetes.

Methods


DPPOS is an ongoing observational study of participants from the DPP randomised trial. For this analysis, diabetes cumulative incidence in DPPOS was calculated for participants with normal glucose regulation or prediabetes status during DPP with and without stratification by previous randomised treatment group. Cox proportional hazards modelling and generalised linear mixed models were used to quantify the effect of previous (DPP) glycaemic status on risk of later (DPPOS) diabetes and normal glucose regulation status, respectively, per SD in change. Included in this analysis were 1990 participants of DPPOS who had been randomly assigned to treatment groups during DPP (736 intensive lifestyle intervention, 647 metformin, 607 placebo). These studies are registered at ClinicalTrials.gov, NCT00004992 (DPP) and NCT00038727 (DPPOS).

Findings


Diabetes risk during DPPOS was 56% lower for participants who had returned to normal glucose regulation versus those who consistently had prediabetes (hazard ratio
0?44, 95% CI 0?37?0?55, p<0?0001) and was unaffected by previous group assignment (interaction test for normal glucose regulation and lifestyle intervention, p=0?1722; normal glucose regulation and metformin, p=0?3304). Many, but not all, of the variables that increased diabetes risk were inversely associated with the chance of a participant reaching normal glucose regulation status in DPPOS. Specifically, previous achievement of normal glucose regulation (odds ratio [OR] 3?18, 95% CI 2?71?3?72, p<0?0001), increased β-cell function (OR 1?28; 95% CI 1?18?1?39, p<0?0001), and insulin sensitivity (OR 1?16, 95% CI 1?08?1?25, p<0?0001) were associated with normal glucose regulation in DPPOS, whereas the opposite was true for prediction of diabetes, with increased β-cell function (HR 0?80, 95% CI 0?71?0?89, p<0?0001) and insulin sensitivity (HR 0?83, 95% CI 0?74?0?94, p=0?0001) having a protective effect. Among participants who did not return to normal glucose regulation in DPP, those assigned to the intensive lifestyle intervention had a higher diabetes risk (HR 1?31, 95% CI 1?03?1?68, p=0?0304) and lower chance of normal glucose regulation (OR 0?59, 95% CI 0?42?0?82, p=0?0014) than did the placebo group in DPPOS.

Interpretation

We conclude that prediabetes is a high-risk state for diabetes, especially in patients who remain with prediabetes despite intensive lifestyle intervention. Reversion to normal glucose regulation, even if transient, is associated with a significantly reduced risk of future diabetes independent of previous treatment group.

http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(12)60525-X/abstract
 
Back
Top Bottom